DK1246814T3 - Forbindelser og fremgangsmåder til modulation af östrogenreceptorer - Google Patents

Forbindelser og fremgangsmåder til modulation af östrogenreceptorer

Info

Publication number
DK1246814T3
DK1246814T3 DK00990966T DK00990966T DK1246814T3 DK 1246814 T3 DK1246814 T3 DK 1246814T3 DK 00990966 T DK00990966 T DK 00990966T DK 00990966 T DK00990966 T DK 00990966T DK 1246814 T3 DK1246814 T3 DK 1246814T3
Authority
DK
Denmark
Prior art keywords
compounds
methods
disclosed
beta
same
Prior art date
Application number
DK00990966T
Other languages
Danish (da)
English (en)
Inventor
Shripad S Bhagwat
Jeffrey A Mckie
Sak Khammungkhune
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/492,939 external-priority patent/US6291456B1/en
Priority claimed from US09/611,156 external-priority patent/US6331562B1/en
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Application granted granted Critical
Publication of DK1246814T3 publication Critical patent/DK1246814T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK00990966T 1999-12-30 2000-12-29 Forbindelser og fremgangsmåder til modulation af östrogenreceptorer DK1246814T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47577699A 1999-12-30 1999-12-30
US09/492,939 US6291456B1 (en) 1998-12-30 2000-01-27 Compounds and methods for modulation of estrogen receptors
US09/611,156 US6331562B1 (en) 1998-12-30 2000-07-06 Compounds and methods for modulation of estrogen receptors
PCT/US2000/035671 WO2001049673A2 (en) 1999-12-30 2000-12-29 Compounds and methods for modulation of estrogen receptors

Publications (1)

Publication Number Publication Date
DK1246814T3 true DK1246814T3 (da) 2005-05-30

Family

ID=27413348

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00990966T DK1246814T3 (da) 1999-12-30 2000-12-29 Forbindelser og fremgangsmåder til modulation af östrogenreceptorer

Country Status (13)

Country Link
EP (1) EP1246814B1 (enExample)
JP (1) JP2003519219A (enExample)
KR (1) KR20020075388A (enExample)
CN (1) CN1281598C (enExample)
AT (1) ATE289300T1 (enExample)
AU (1) AU781282B2 (enExample)
CA (1) CA2396059A1 (enExample)
DE (1) DE60018215T2 (enExample)
DK (1) DK1246814T3 (enExample)
ES (1) ES2238034T3 (enExample)
IL (1) IL150463A0 (enExample)
PT (1) PT1246814E (enExample)
WO (1) WO2001049673A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
EP1177787A3 (en) * 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
EP1281710A1 (en) * 2001-08-03 2003-02-05 CHIESI FARMACEUTICI S.p.A. 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
US7148252B2 (en) * 2001-10-03 2006-12-12 Signal Pharmaceuticals, Llc Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis
US7217734B2 (en) 2001-11-19 2007-05-15 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
WO2003047504A2 (en) * 2001-11-29 2003-06-12 Gtx Inc. Prevention and treatment of androgen-deprivation induced osteoporosis
AU2005202072B2 (en) * 2001-11-29 2008-10-23 Gtx, Inc. Prevention and treatment of androgen-deprivation induced conditions
AU2003239155B2 (en) * 2002-04-19 2008-12-04 Novartis Ag Benzopyranone compounds, compositions thereof, and methods of treatment therewith
US7091235B2 (en) 2002-10-15 2006-08-15 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer
US7674783B2 (en) * 2002-11-22 2010-03-09 Dimera Inc. Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease
MXPA05011243A (es) 2003-04-21 2005-12-15 Lilly Co Eli Benzopiranos substituidos como agonistas selectivos del receptor beta de estrogeno.
ES2338119T3 (es) 2003-04-21 2010-05-04 Eli Lilly And Company Benzopiranos sustituidos como agonistas selectivos del receptor-beta de estrogeno.
US7098340B2 (en) * 2003-05-14 2006-08-29 Warner Lambert Company Llc Benzyl sulfonamide derivatives
WO2005028472A1 (en) * 2003-09-15 2005-03-31 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods of treatment therewith
CA2595472A1 (en) * 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel coumarin derivatives as ion channel openers
WO2008002490A2 (en) * 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
PL2568806T3 (pl) 2010-05-12 2017-03-31 Radius Health, Inc. Schematy lecznicze
EP2621901B1 (en) 2010-09-28 2015-07-29 Radius Health, Inc Selective androgen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
SI3122426T1 (sl) 2014-03-28 2023-04-28 Duke University Zdravljenje raka dojk z uporabo selektivnih modulatorjev estrogenskih receptorjev
CN105801544A (zh) * 2016-04-18 2016-07-27 中国药科大学 3-芳基-4-芳香胺-香豆素衍生物及其制备方法和医药用途
CN105801543B (zh) * 2016-04-18 2019-08-02 中国药科大学 4-芳香胺-香豆素衍生物及其制备方法和医药用途
PT3474841T (pt) 2016-06-22 2022-06-20 Radius Health Inc Métodos de tratamento do cancro de mama ar+
CN106492204A (zh) * 2016-12-27 2017-03-15 郑州郑先医药科技有限公司 一种治疗白内障的药物组合物
CN106727637A (zh) * 2016-12-27 2017-05-31 郑州郑先医药科技有限公司 一种治疗白内障的西药组合物及其用途
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883118A (en) * 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
US5726202A (en) * 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
IL124882A0 (en) * 1996-01-11 1999-01-26 Novo Nordisk As Use of 3, 4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
ATE248157T1 (de) * 1998-12-30 2003-09-15 Signal Pharm Inc Verbindungen und verfahren zur modulation von estrogen rezeptoren

Also Published As

Publication number Publication date
DE60018215D1 (de) 2005-03-24
CN1437591A (zh) 2003-08-20
CN1281598C (zh) 2006-10-25
IL150463A0 (en) 2002-12-01
WO2001049673A2 (en) 2001-07-12
EP1246814B1 (en) 2005-02-16
EP1246814A2 (en) 2002-10-09
AU3077101A (en) 2001-07-16
AU781282B2 (en) 2005-05-12
WO2001049673A3 (en) 2001-12-06
HK1058521A1 (en) 2004-05-21
ATE289300T1 (de) 2005-03-15
ES2238034T3 (es) 2005-08-16
KR20020075388A (ko) 2002-10-04
CA2396059A1 (en) 2001-07-12
DE60018215T2 (de) 2006-02-09
JP2003519219A (ja) 2003-06-17
PT1246814E (pt) 2005-07-29

Similar Documents

Publication Publication Date Title
DK1246814T3 (da) Forbindelser og fremgangsmåder til modulation af östrogenreceptorer
DK1140889T3 (da) Forbindelser og metoder til modulation af estrogen-receptorer
WO2000055137A8 (en) Compounds and methods for modulation of estrogen receptors
MY115784A (en) Estrogen agonists/antagonists
BR0010215A (pt) Derivados de indolina como antagonistas de progesterona
MX9505249A (es) Agonistas de estrogeno.
CR6478A (es) Moduladores del receptor glucocorticoide
ATE521599T1 (de) Heterocyclische modulatoren von nukleären rezeptoren
NO20020913L (no) Androgenreseptor-modulatorforbindelser og fremgangsmåter
AU5467699A (en) Substituted isoxazole as estrogen receptor modulators
DK1169417T3 (da) Hydrobehandling ved anvendelse af bulk-gruppe VIII/gruppe VIB katalysatorer
PE20040678A1 (es) Moduladores de los receptores selectivos de estrogenos
DE59911879D1 (de) Verwendung von biogenen estrogensulfamaten zur hormonsubstitutionstherapie
WO2007016385A3 (en) Use of substituted 5-amino-1h-pyrrole-2-carbonitrile derivatives as progesterone receptor modulators
BR0110087A (pt) Compostos para modular proliferação celular
NZ515353A (en) Cyclothiocarbamate derivatives as progesterone receptor modulators
DE69933679D1 (de) Darstellung des profils und katalogisierung von exprimierten proteinmarkern
PT1273572E (pt) Piperazinas substituidas com tiofeno uteis no tratamento da hiperplasia prostatica benigna
ATE254122T1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
DK1196428T3 (da) 11-beta-aryl-17,17-spirothiolan-substituerede steroider
MY137604A (en) Benzopyranone compounds, compositions thereof, and methods of treatment therewith
DE60040764D1 (de) Mesoprogestinen (progesteron-rezeptor-modulatoren) als bestandteil von zusammensetzungen für die hormonersatztherapie
Charnock-Jones et al. Vascular endothelial growth factor and corpus luteum angiogenesis
WO2003041654A3 (en) Anti-estrogen and immune modulator combinations for treating breast cancer
Tsai et al. Evidence for Up-Regulation of Estrogen Receptor mRNA in Chondrocytes of Early Osteoarthritic Rabbits